Biomarker & Intervention Discovery

Carpal Tunnel Syndrome

This page lists 8 druggable gene targets, 36 approved or trial-tested drug candidates and 15 recent clinical trials for Carpal Tunnel Syndrome, with each agent ranked by the strength of its evidence (clinical, mechanistic or correlative). Candidates include existing drugs that could be repurposed. Sources are linked so you can check every claim.

US DALYs4.08MWHO GHE 2021 · all ages
Global DALYs45.69MWHO GHE 2021 · worldwide
US mortality12.5K deaths/yrWHO GHE 2021
Global mortality110.0K deaths/yrWHO GHE 2021 · worldwide
Spontaneous remissionMild CTS: spontaneous resolution in 30-40% within 12 months without treatment; moderate-severe: <5% spontaneous…
Best-intervention remissionSurgical decompression (carpal tunnel release, CTR): 90% symptom resolution at 12 months; 85% satisfaction at 5 years…
Gap sizeSmall — surgery is highly effective; the question is appropriate timing and selecting patients for non-surgical…
Primary barrierpractice/framing
Full remission profile →

Remission & chronicity

Spontaneous remission
Mild CTS: spontaneous resolution in 30-40% within 12 months without treatment; moderate-severe: <5% spontaneous resolution; pregnancy-related CTS resolves in 80% post-delivery
Best-intervention remission
Surgical decompression (carpal tunnel release, CTR): 90% symptom resolution at 12 months; 85% satisfaction at 5 years; superior to splinting at 6 months (SEVIORAL trial); corticosteroid injection: 75% improvement at 4 weeks, 50% at 6 months, 20% at 12 months
Gap size
Small — surgery is highly effective; the question is appropriate timing and selecting patients for non-surgical management
Primary barrier
practice/framing
Surgery is underused in some health systems where patients are kept on conservative management (splinting, cortisone) for years with progressive nerve damage; conversely, overused in mild cases where non-surgical management could suffice; ergonomic intervention is chronically under-addressed

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

IL6 181NR3C1 264PTGS2 309SCN9A 280TGFB1 62TNF 287TRPV1 187TTR 153
Therapeutic Agent Effect Direction Evidence Tier Potency Source
CLAZAKIZUMAB ↓ inhibits Mechanistic
MIDOSTAURIN ? unclear Mechanistic
ECHINACEA EXTRACT ? unclear Mechanistic
NELFINAVIR ? unclear Mechanistic
SELECTIVE ESTROGEN RECEPTOR MODULATOR ? unclear Mechanistic
SIGNAL TRANSDUCTION INHIBITOR ? unclear Mechanistic
OLOKIZUMAB ? unclear Mechanistic
IBUDILAST ? unclear Mechanistic
VITAMIN A PALMITATE ? unclear Mechanistic
IFOSFAMIDE ? unclear Mechanistic
SITAGLIPTIN ? unclear Mechanistic
METRONIDAZOLE ? unclear Mechanistic
PEGINTERFERON ALFA-2A ? unclear Mechanistic
PACIBEKITUG ↓ inhibits Mechanistic
PEGINTERFERON ALFA-2B ? unclear Mechanistic
SIRUKUMAB ↓ inhibits Mechanistic
HMG-COA REDUCTASE INHIBITOR ? unclear Mechanistic
SAFINGOL ? unclear Mechanistic
ENZYME INHIBITOR ? unclear Mechanistic
CISPLATIN ? unclear Mechanistic
GALLIUM NITRATE ? unclear Mechanistic
RITUXIMAB ? unclear Mechanistic
INFLIXIMAB ? unclear Mechanistic
C326 ? unclear Mechanistic
GEMFIBROZIL ? unclear Mechanistic
ZILTIVEKIMAB ? unclear Mechanistic
INSULIN, REGULAR, HUMAN ? unclear Mechanistic
OSIMERTINIB ? unclear Mechanistic
BINETRAKIN ? unclear Mechanistic
ALOGLIPTIN ? unclear Mechanistic
TENELIGLIPTIN ? unclear Mechanistic
CHINESE HERBS ? unclear Mechanistic
TOCILIZUMAB ? unclear Mechanistic
LINAGLIPTIN ? unclear Mechanistic
DOCETAXEL ANHYDROUS ? unclear Mechanistic
VILDAGLIPTIN ? unclear Mechanistic
LINEZOLID ? unclear Mechanistic
SELENIUM ? unclear Mechanistic
SAQUINAVIR ? unclear Mechanistic
PAREGORIC ? unclear Mechanistic

Showing top 40 of 181 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
METHYLPREDNISOLONE ↑ activates Mechanistic
FOSDAGROCORAT ↑ activates Mechanistic
ZK216348 ↑ activates Mechanistic
PHENYLMERCURIC ACETATE ? unclear Mechanistic
TNF-ALPHA ? unclear Mechanistic
HYDROCORTAMATE HYDROCHLORIDE ↑ activates Mechanistic
TRIAMCINOLONE ↑ activates Mechanistic
BUDESONIDE ↑ activates Mechanistic
ANTICONVULSANT AGENT ? unclear Mechanistic
FLUTICASONE FUROATE ↑ activates Mechanistic
METHYLPREDNISOLONE ACETATE ↑ activates Mechanistic
DAGROCORAT ↑ activates Mechanistic
MIFEPRISTONE ↓ inhibits Mechanistic 0.24 nM (Ki)
TESTOSTERONE PROPIONATE ? unclear Mechanistic
FLURANDRENOLIDE ↑ activates Mechanistic
CHEMBL:CHEMBL1915271 ? unclear Mechanistic
CHRYSIN ? unclear Mechanistic
FLUOXYMESTERONE ? unclear Mechanistic
LOTEPREDNOL ↑ activates Mechanistic
DIFLUPREDNATE ↑ activates Mechanistic
CORT 108297 ↓ inhibits Mechanistic
PROGESTERONE ? unclear Mechanistic 30.5 nM (Ki)
BETAMETHASONE SODIUM PHOSPHATE ↑ activates Mechanistic
ANTIDEPRESSANT AGENT ? unclear Mechanistic
HYDROCORTISONE BUTYRATE ↑ activates Mechanistic
VELSECORAT ↑ activates Mechanistic
FLUMETHASONE PIVALATE ↑ activates Mechanistic
AMCINONIDE ↑ activates Mechanistic
CYPROTERONE ACETATE ↓ inhibits Mechanistic
C108297 ↑ activates Mechanistic
COMPOUND 17 [PMID: 29741897] ↑ activates Mechanistic
FLUOCINONIDE ↑ activates Mechanistic
MAPRACORAT ↑ activates Mechanistic
CLOBETASOL PROPIONATE ↑ activates Mechanistic
CHEMBL:CHEMBL210411 ? unclear Mechanistic
FLUOCINOLONE ACETONIDE ↑ activates Mechanistic
BETAMETHASONE ↑ activates Mechanistic
BECLOMETHASONE DIPROPIONATE ↑ activates Mechanistic
FLUNISOLIDE ANHYDROUS ↑ activates Mechanistic
CORTISONE ACETATE ↑ activates Mechanistic

Showing top 40 of 264 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
CURCUMIN PYRAZOLE ? unclear Mechanistic
CAPECITABINE ? unclear Mechanistic
DIFLUNISAL ↓ inhibits Mechanistic
ROFECOXIB ↓ inhibits Mechanistic 530.0 nM (IC50)
KETOROLAC TROMETHAMINE ↓ inhibits Mechanistic
DEXIBUPROFEN ↓ inhibits Mechanistic
BALSALAZIDE ? unclear Mechanistic
ESFLURBIPROFEN ↓ inhibits Mechanistic
NAPROXEN ETEMESIL ? unclear Mechanistic
SUPROFEN ↓ inhibits Mechanistic
PEPTIDE 30 [PMID: 27019010] ↓ inhibits Mechanistic
NEPAFENAC ↓ inhibits Mechanistic
APRICOXIB ↓ inhibits Mechanistic
APAZONE ↓ inhibits Mechanistic
SALICYLIC ACID ? unclear Mechanistic
TIAPROFENIC ACID ? unclear Mechanistic
KETOPROFEN ↓ inhibits Mechanistic
RESERPINE ? unclear Mechanistic
NS-398 ↓ inhibits Mechanistic
NABUMETONE ↓ inhibits Mechanistic
SULINDAC ↓ inhibits Mechanistic
ETODOLAC ↓ inhibits Mechanistic
MEFENAMIC ACID ↓ inhibits Mechanistic
DICLOFENAC SODIUM ↓ inhibits Mechanistic
ETORICOXIB ↓ inhibits Mechanistic
VALDECOXIB ↓ inhibits Mechanistic
IBUFENAC ↓ inhibits Mechanistic
DEXKETOPROFEN ↓ inhibits Mechanistic
GLAFENINE ↓ inhibits Mechanistic
COMPOUND 9 [KUMAR ET AL., 2019] ↓ inhibits Mechanistic
RESVERATROL ↓ inhibits Mechanistic
SWE101 ↓ inhibits Mechanistic
INDOMETHACIN ↓ inhibits Mechanistic 5.9 nM (IC50)
NAPROXCINOD ↓ inhibits Mechanistic
HR1405-01 ↓ inhibits Mechanistic
DICLOFENAC ETALHYALURONATE SODIUM ↓ inhibits Mechanistic
COMPOUND 12A [PMID: 29031075] ↓ inhibits Mechanistic
TOLMETIN SODIUM ↓ inhibits Mechanistic
OXYPHENBUTAZONE ↓ inhibits Mechanistic
DICLOFENAC POTASSIUM ↓ inhibits Mechanistic

Showing top 40 of 309 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
TETRODOTOXIN ↓ inhibits Mechanistic
XEN403 ↓ inhibits Mechanistic
IRAMPANEL ↓ inhibits Mechanistic
XEN907 ↓ inhibits Mechanistic
N-ME-AMINOPYRIMIDINONE 9 ↓ inhibits Mechanistic
PF‐06526290 ↓ inhibits Mechanistic
QUINIDINE POLYGALACTURONATE ↓ inhibits Mechanistic
VIXOTRIGINE ↓ inhibits Mechanistic
LIDOCAINE ↓ inhibits Mechanistic
FUNAPIDE ↓ inhibits Mechanistic
CD2+ ↓ inhibits Mechanistic
PHENYTOIN SODIUM ↓ inhibits Mechanistic
HEXYLCAINE HYDROCHLORIDE ↓ inhibits Mechanistic
ESLICARBAZEPINE ACETATE ↓ inhibits Mechanistic
DICHLOROBENZYL ALCOHOL ↓ inhibits Mechanistic
PROPOFOL ? unclear Mechanistic
OXCARBAZEPINE ↓ inhibits Mechanistic
ORPHENADRINE CITRATE ↓ inhibits Mechanistic
NERISPIRDINE ↓ inhibits Mechanistic
CHLOROPROCAINE HYDROCHLORIDE ↓ inhibits Mechanistic
MEPHENYTOIN ↓ inhibits Mechanistic
ANP-230 ↓ inhibits Mechanistic
ABBV-318 ↓ inhibits Mechanistic
MEPIVACAINE HYDROCHLORIDE ↓ inhibits Mechanistic
AMOROLFINE ↓ inhibits Mechanistic
RUFINAMIDE ↓ inhibits Mechanistic
EVENAMIDE ↓ inhibits Mechanistic
SAFINAMIDE ? unclear Mechanistic
NKTR-171 ↓ inhibits Mechanistic
RG6029 ↓ inhibits Mechanistic
RALFINAMIDE ↓ inhibits Mechanistic
ZONISAMIDE ↓ inhibits Mechanistic
BIIB-095 ? unclear Mechanistic
RG7893 ↓ inhibits Mechanistic
ARTICAINE HYDROCHLORIDE ↓ inhibits Mechanistic
DISOPYRAMIDE PHOSPHATE ↓ inhibits Mechanistic
PROPOXYCAINE HYDROCHLORIDE ↓ inhibits Mechanistic
TOCAINIDE HYDROCHLORIDE ↓ inhibits Mechanistic
TETRACAINE HYDROCHLORIDE ↓ inhibits Mechanistic
MERETHOXYLLINE PROCAINE ↓ inhibits Mechanistic

Showing top 40 of 280 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
LY-2382770 ↓ inhibits Mechanistic
ETOPOSIDE ? unclear Mechanistic
BROXURIDINE ? unclear Mechanistic
INOSITOL ? unclear Mechanistic
D-ALPHA-TOCOPHEROL ? unclear Mechanistic
STREPTOZOCIN ? unclear Mechanistic
PROTEASOME INHIBITOR ? unclear Mechanistic
FRESOLIMUMAB ↓ inhibits Mechanistic
THERAPEUTIC ANDROGEN ? unclear Mechanistic
GALUNISERTIB ? unclear Mechanistic
TOREMIFENE ? unclear Mechanistic
TRETINOIN ? unclear Mechanistic
BINTRAFUSP ALFA ~ modulates Mechanistic
PIRFENIDONE ? unclear Mechanistic
DOXORUBICIN HYDROCHLORIDE ? unclear Mechanistic
GOSSYPOL ? unclear Mechanistic
EMODIN ? unclear Mechanistic
IDOXURIDINE ? unclear Mechanistic
HYDROCORTISONE BUTYRATE ? unclear Mechanistic
CLADRIBINE ? unclear Mechanistic
TG-C ? unclear Mechanistic
ASPIRIN ? unclear Mechanistic
DISITERTIDE ? unclear Mechanistic
RAMIPRIL ? unclear Mechanistic
ANTISENSE OLIGONUCLEOTIDES ? unclear Mechanistic
HEPARAN SULFATE ? unclear Mechanistic
TRIAMCINOLONE ? unclear Mechanistic
ESTRADIOL VALERATE ? unclear Mechanistic
AMIFOSTINE ANHYDROUS ? unclear Mechanistic
KEYHOLE LIMPET HEMOCYANIN ? unclear Mechanistic
LUSPATERCEPT ↓ inhibits Mechanistic
ATENOLOL ? unclear Mechanistic
GALLIUM NITRATE ? unclear Mechanistic
ANTIOXIDANT ? unclear Mechanistic
FENRETINIDE ? unclear Mechanistic
GENISTEIN ? unclear Mechanistic
RETINOIC ACID AGENT ? unclear Mechanistic
OCTREOTIDE ACETATE ? unclear Mechanistic
THERAPEUTIC MELATONIN ? unclear Mechanistic
TCDD ? unclear Mechanistic

Showing top 40 of 62 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
DICLOFENAC SODIUM ? unclear Mechanistic
RDP58 ? unclear Mechanistic
METHYLENE BLUE ? unclear Mechanistic
ORTATAXEL ? unclear Mechanistic
CERTOLIZUMAB PEGOL ↓ inhibits Mechanistic
OZORALIZUMAB ↓ inhibits Mechanistic
THALIDOMIDE ? unclear Mechanistic
HUANG LIAN ? unclear Mechanistic
GOLIMUMAB ↓ inhibits Mechanistic
CYCLOSPORINE ? unclear Mechanistic
DOCETAXEL ANHYDROUS ? unclear Mechanistic
HALOFUGINONE ? unclear Mechanistic
ETANERCEPT ↓ inhibits Mechanistic
ISIS 104838 ? unclear Mechanistic
GEMCITABINE ? unclear Mechanistic
INDOMETHACIN ? unclear Mechanistic
INSULIN, REGULAR, HUMAN ? unclear Mechanistic
DIDANOSINE ? unclear Mechanistic
5,7-DIHYDROXY-4-METHYLCOUMARIN ? unclear Mechanistic
SOBLIDOTIN ? unclear Mechanistic
STAVUDINE ? unclear Mechanistic
CISPLATIN ? unclear Mechanistic
MEROPENEM ANHYDROUS ? unclear Mechanistic
AMPHOTERICIN B LIPOSOMAL ? unclear Mechanistic
MIDAZOLAM HYDROCHLORIDE ? unclear Mechanistic
RIFAMPIN ? unclear Mechanistic
AVX-470 ? unclear Mechanistic
KETOROLAC TROMETHAMINE ? unclear Mechanistic
PRAZOSIN HYDROCHLORIDE ? unclear Mechanistic
RISPERIDONE ? unclear Mechanistic
BENZO[E]PYRENE ? unclear Mechanistic
ETHAMBUTOL HYDROCHLORIDE ? unclear Mechanistic
REMTOLUMAB ↓ inhibits Mechanistic
SPIRONOLACTONE ? unclear Mechanistic
OMEPRAZOLE ? unclear Mechanistic
CARBOPLATIN ? unclear Mechanistic
MITOMYCIN C ANALOG KW-2149 ? unclear Mechanistic
NAFAMOSTAT ? unclear Mechanistic
ABBV-3373 ~ modulates Mechanistic
BACILLUS CALMETTE-GUERIN ANTIGEN ? unclear Mechanistic

Showing top 40 of 287 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
RHTX ↑ activates Mechanistic
ABT-102 ↓ inhibits Mechanistic
ASIVATREP ↓ inhibits Mechanistic
BCTC ↓ inhibits Mechanistic
MAVATREP ↓ inhibits Mechanistic
POLYGODIAL ? unclear Mechanistic
ALLICIN ↓ inhibits Mechanistic
JTS-653 ↓ inhibits Mechanistic
SB452533 ↓ inhibits Mechanistic
MR-1817 ↓ inhibits Mechanistic
GRC-6211 ↓ inhibits Mechanistic
ACETAMINOPHEN ↑ activates Mechanistic
DWP05195 ↓ inhibits Mechanistic
STREPTOZOCIN ? unclear Mechanistic
CAPSAICIN ↑ activates Mechanistic 19.95 nM (EC50)
AMG517 ↓ inhibits Mechanistic
5S-HETE ↑ activates Mechanistic
BENZYL ISOTHIOCYANATE ? unclear Mechanistic
MASOPROCOL ? unclear Mechanistic
[3H]RESINIFERATOXIN ↑ activates Mechanistic
[3H]A778317 ↓ inhibits Mechanistic
CAPSAZEPINE ↓ inhibits Mechanistic 120.0 nM (Ki)
NABIXIMOLS ? unclear Mechanistic
H+ ↑ activates Mechanistic
RECOMBINANT TUMOR NECROSIS FACTOR FAMILY PROTEIN ? unclear Mechanistic
NADA ↓ inhibits Mechanistic
ZUCAPSAICIN ↑ activates Mechanistic
SB366791 ↓ inhibits Mechanistic
GRC-15300 ? unclear Mechanistic
MRS-1477 ~ modulates Mechanistic
ANANDAMIDE ↑ activates Mechanistic
JNJ17203212 ↓ inhibits Mechanistic
LEVODOPA ? unclear Mechanistic
INDOMETHACIN ? unclear Mechanistic
AZD1386 ↓ inhibits Mechanistic
CAMPHOR OIL ↑ activates Mechanistic
ISOPROPYL ISOTHIOCYANATE ? unclear Mechanistic
VOACANGINE ? unclear Mechanistic
FERRUGINENE B ? unclear Mechanistic
PHENYLACETYLRINVANIL ↑ activates Mechanistic

Showing top 40 of 187 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
APIGENIN ? unclear Mechanistic 18000.0 nM (IC50)
ACORAMIDIS ~ modulates Mechanistic 314.0 nM (Kd)
INOTERSEN ? unclear Mechanistic
ACORAMIDIS HYDROCHLORIDE ~ modulates Mechanistic
TAFAMIDIS ~ modulates Mechanistic 274.0 nM (Kd)
MASOPROCOL ? unclear Mechanistic
PATISIRAN ? unclear Mechanistic
ETHYL CAFFEATE ? unclear Mechanistic 23000.0 nM (EC50)
REVUSIRAN ? unclear Mechanistic
EPLONTERSEN ? unclear Mechanistic
CAFFEIC ACID PHENETHYL ESTER ? unclear Mechanistic 8600.0 nM (EC50)
DIHYDROGUAIARETIC ACID ? unclear Mechanistic 6300.0 nM (EC50)
VUTRISIRAN ? unclear Mechanistic
TAFAMIDIS MEGLUMINE ~ modulates Mechanistic
BENZYL CAFFEATE ? unclear Mechanistic 16000.0 nM (EC50)
PATISIRAN SODIUM ? unclear Mechanistic
INOTERSEN SODIUM ? unclear Mechanistic
VUTRISIRAN SODIUM ? unclear Mechanistic
EPLONTERSEN SODIUM ? unclear Mechanistic
TRICLOSAN ↓ inhibits Mechanistic 53500.0 nM (IC50)
CHEMBL394034 ↓ inhibits Mechanistic 120.0 nM (Kd)
CHEMBL240165 ↓ inhibits Mechanistic 42.0 nM (Kd)
CHEMBL241454 ↓ inhibits Mechanistic 27.0 nM (Kd)
CHEMBL241453 ↓ inhibits Mechanistic 88.0 nM (Kd)
CHEMBL240808 ↓ inhibits Mechanistic 27.0 nM (Kd)
CHEMBL438498 ↓ inhibits Mechanistic 0.2 nM (Kd)
CHEMBL240806 ↓ inhibits Mechanistic 0.3 nM (Kd)
CHEMBL240805 ↓ inhibits Mechanistic 5.7 nM (Kd)
CHEMBL240804 ↓ inhibits Mechanistic 13.9 nM (Kd)
DEXTROTHYROXINE ↓ inhibits Mechanistic 7170.0 nM (IC50)
CHEMBL241025 ↓ inhibits Mechanistic 1940.0 nM (IC50)
CHEMBL240807 ↓ inhibits Mechanistic 3160.0 nM (IC50)
CHEMBL392872 ↓ inhibits Mechanistic 41000.0 nM (IC50)
CHEMBL238590 ↓ inhibits Mechanistic 45000.0 nM (IC50)
CHEMBL392873 ↓ inhibits Mechanistic 55000.0 nM (IC50)
CHEMBL241575 ↓ inhibits Mechanistic 20000.0 nM (IC50)
CHEMBL241573 ↓ inhibits Mechanistic 20000.0 nM (IC50)
FLUFENAMIC ACID ↓ inhibits Mechanistic 2900.0 nM (IC50)
CHEMBL60569 ↓ inhibits Mechanistic 6300.0 nM (IC50)
CHEMBL571374 ↓ inhibits Mechanistic 11000.0 nM (IC50)

Showing top 40 of 153 agents ranked by evidence tier.


Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Carpal Tunnel Syndrome: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

NCT07825155 Phase: Early 1 Started: 2026-03-15

Carpal tunnel syndrome (CTS) is a common peripheral nerve entrapment disorder caused by compression of the median nerve at the wrist. This study is a comparative study designed to evaluate the efficacy of three ultrasound-guided injection treatments for patients with mild to moderate CTS: hyaluronic...

NCT07723313 Phase: Early 1 Started: 2025-12-15

Carpal Tunnel Syndrome (CTS) is a compressive neuropathy caused by chronic compression of the median nerve within the carpal tunnel, resulting in pain, numbness, tingling, and impaired hand function. This study is a randomized controlled trial with a pre- and post-intervention experimental design to...

NCT07105540 Phase: 4 Started: 2025-08-05

The aim of this study is to compare the effects of ultrasound-guided hydrodissection with 5% dextrose and perineural corticosteroid injection on the clinical parameters of carpal tunnel syndrome, as well as to evaluate the long-term efficacy of these treatments.

NCT07312123 Phase: N/A Started: 2025-12-08

Carpal Tunnel Syndrome (CTS) is a common condition that causes numbness, tingling, pain, and weakness in the hand due to compression of the median nerve at the wrist. It can affect daily activities, work performance, and quality of life. While surgery is effective in severe cases, many patients with...

NCT05306548 Phase: 4 Started: 2022-04-08

Carpal tunnel syndrome (CTS) causes numbness and pain in the hand and arm, and is an important cause of work absence and disability. The aim of the NOR-CACTUS Trial is to compare outcomes of a treatment strategy where the initial treatment is up to two ultrasound-guided corticosteroid injections, fo...

NCT05416515 Phase: 2 Started: 2022-10-09

This research study is being conducted to investigate the safety and effectiveness of the drug Fisetin for mild or moderate carpal tunnel syndrome (CTS).

NCT07002892 Phase: N/A Started: 2025-01-01

Effectiveness of corticosteroid and 5% dextrose versus USG-guided ozone injections in patients with carpal tunnel syndrome: Three blind randomized studies

NCT06940557 Phase: 2/3 Started: 2023-12-01

The goal of this clinical trial is to assess the effectiveness and safety of an oral combination of alpha lipoic acid (ALA) and vitamin B complex in treating mild to moderate carpal tunnel syndrome (CTS) in adults. The main questions it aims to answer are: * Does the combination of ALA and vitamin B...

NCT06249503 Phase: 4 Started: 2023-02-01

PRP represents a promising, nonsurgical option for patients with carpal tunnel syndrome (CTS) with improvement in symptoms compared to placebo, conservative treatment, and local corticosteroid injections at 3-months postintervention. However, the lack of significant long-term results in pain and fun...

NCT05475808 Phase: 4 Started: 2022-08-01

It is aimed to compare the effects of different conservative methods on the clinical condition of the patients, hand grip and pinch strengths and wrist muscle strengths in patients with carpal tunnel syndrome.

NCT04833777 Phase: N/A Started: 2021-07-01

This study is being conducted to determine whether addition of a longer-acting local anesthetic to our current anesthetic protocol improves the post-operative pain after carpal tunnel release. Participants undergoing carpal tunnel release (CTR) will be randomly assigned to one of two groups: the sta...

NCT06349265 Phase: 4 Started: 2023-10-02

This study was a prospective randomized double-blind clinical trial conducted at the Physical Medicine and Rehabilitation Clinic of a local research and training hospital in Turkey from October 2023 and May 2024. Patients diagnosed with CTS were classified into three groups: severe, mild, and modera...

NCT06349824 Phase: 4 Started: 2023-10-10

USG guided injections to relieve carpal tunnel syndrome with dextrose water or steroid or PRP

NCT06282640 Phase: 4 Started: 2021-12-30

Therefore, we aimed to evaluate the effectiveness of vitamin D replacement therapy on pain, electrophysiological parameters, ultrasonographic measurement results and functional status scales in CTS patients with low serum vitamin D levels.

NCT06209957 Phase: 4 Started: 2017-06-01

This clinical trial aims to evaluate the effect of a single local platelet-rich plasma injection Versus local steroid injection in treating mild idiopathic carpal tunnel syndrome regarding pain relief and function improvement and electrophysiological studies of the median nerve as a baseline and dur...


Agents Found By Disease-Level Search

Searched directly from “Carpal Tunnel Syndrome” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 8-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

36 agents shown (approved or with trial evidence) — 32 not found by the gene-target search above.

platelet rich plasmaNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT06249503 NCT02800200

shock waveNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT02800200 NCT06214286

Carpal tunnel releaseNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT07594821 NCT07509437

Ischemic Compression (thumb Pressure)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00634738

Lidocaine

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT06188221

CorticoidsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06188221

CTS-6 Evaluation ToolNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07420049

Ibuprofen ArginineNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04025203

GabapentinNOT in gene-target list

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT04025203

wrist splintNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06189651

5% dextrose injection using USG-guided nerve hydrodissection methodNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06189651

Sono-guided injection with ES135NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06328166

Nerve conduction studiesNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06115187

Pulsed RadiofrequencyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02217293

Kinesio tapingNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05475197

pulsed electromagnetic fieldNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02745652

Incisionless Threaded Carpal TunnelNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04101955

Standard Mini-Open Carpal TunnelNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04101955

dextrose 5% median nerve hydrodissectionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05725460

Study groupNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03802448

Control groupNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03802448

5% DextroseNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07105540

Betamethasone and local anestheticNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07105540

Acetaminophen

· 1 trial · source: ClinicalTrials.gov
NCT02313675

Ketorolac Tromethamine

· 1 trial · source: ClinicalTrials.gov
NCT02313675

Combined carpal tunnel and lacertus releaseNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07594821

Ropivacaine

Phase 1 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT01993290

chirurgie canal carpienNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06693167

extracorporeal shockwave therapyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06321276

Distal Radius Fracture Fixation with Observation.NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07509437

Neuromuscular tapingNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02406794

Aquatic TherapyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06905769

Neuro-Dynamic TechniqueNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06905769

two-component skin adhesive Glubran Tiss 2®NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05808855

skin stitched with transcutaneous nylon sutureNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05808855

MonocrylNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03950401

Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.